13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001795097
Total reported value
$544.2M
$544.2M
56 檔
43.3%
In Q1 2025, Privium Fund Management B.V.'s U.S. equity holdings reached a combined market value of $544.2M, distributed across 56 disclosed stock positions.
During Q1 2025, Privium Fund Management B.V.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SPOT, TSLA, SHOP) accounted for 43.3% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPOT | Spotify Technology S.A. | Stock-Comm Services | 20.98% | -2.12% | — | |
| 2 | TSLA | Tesla Inc | Stock-Consumer Disc | 14.96% | +0.44% | — | |
| 3 | SHOP | Shopify Inc - Class A | Stock-Tech | 10.38% | -2.29% | — | |
| 4 | PLTR | Palantir Technologies Inc-a | Stock-Tech | 7.98% | -1.80% | -2.70% | |
| 5 | SE | Sea Ltd-adr | Stock-Comm Services | 7.15% | -2.38% | EXIT | |
| 6 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 7.03% | +0.71% | — | |
| 7 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.36% | +0.49% | -3.32% | |
| 8 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.10% | +0.13% | +0.30% | |
| 9 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.09% | -1.28% | +65.33% | |
| 10 | NVDA | Nvidia CORP | Stock-Tech | 2.07% | +0.04% | — | |
| 11 | SNOW | Snowflake Inc | Stock-Tech | 1.86% | — | -36.00% | |
| 12 | NET | Cloudflare Inc - Class A | Stock-Tech | 1.76% | — | — | |
| 13 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 1.73% | +0.05% | — | |
| 14 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.60% | -0.27% | -15.27% | |
| 15 | QURE | uniQure N.V. | Stock-Other | 1.60% | +1.12% | -21.97% | |
| 16 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.43% | — | — | |
| 17 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.33% | +0.35% | — | |
| 18 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.25% | -0.09% | -28.57% | |
| 19 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.05% | -0.20% | — | |
| 20 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.96% | — | -43.41% | |
| 21 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.75% | -0.03% | +8.83% | |
| 22 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.64% | — | — | |
| 23 | MRNA | Moderna Inc | Stock-Healthcare | 0.56% | +0.07% | -8.37% | |
| 24 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.53% | +0.03% | +71.72% | |
| 25 | ABEV | Ambev Sa-adr | Stock-Consumer Staples | 0.49% | -0.12% | +23.28% | |
| 26 | CPNG | Coupang Inc | Stock-Consumer Disc | 0.48% | — | -42.28% | |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.40% | -0.21% | — | |
| 28 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.35% | +0.16% | -18.81% | |
| 29 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.33% | — | -41.10% | |
| 30 | IMVT | Immunovant Inc | Stock-Other | 0.32% | — | — | |
| 31 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.31% | +0.53% | +288.65% | |
| 32 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.27% | — | +8.15% | |
| 33 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.24% | -0.10% | +29.03% | |
| 34 | PFE | Pfizer Inc | Stock-Healthcare | 0.21% | -0.31% | EXIT | |
| 35 | VAL | Valaris Limited | Stock-Energy | 0.21% | — | +42.59% | |
| 36 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.21% | +0.11% | -48.02% | |
| 37 | NOV | Nov Inc | Stock-Energy | 0.20% | -0.02% | +15.99% | |
| 38 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.16% | — | — | |
| 39 | AIG | American International Group | Stock-Financials | 0.15% | — | -19.20% | |
| 40 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.14% | -0.11% | +15.99% | |
| 41 | PAAS | Pan American Silver CORP | Stock-Materials | 0.14% | -0.04% | EXIT | |
| 42 | SEA1EUR | Seabridge Gold Inc | Stock-Other | 0.13% | -0.15% | EXIT | |
| 43 | EMX | Emx Royalty CORP | Stock-Other | 0.12% | — | — | |
| 44 | VZLA | Vizsla Silver CORP | Stock-Other | 0.11% | — | +65.20% | |
| 45 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.11% | -0.11% | +8.26% | |
| 46 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.11% | — | +111.88% | |
| 47 | URNM | Sprott Uranium Miners ETF | ETF-Other | 0.10% | -0.04% | EXIT | |
| 48 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.10% | +0.01% | +8.63% | |
| 49 | NE | Noble Corporation plc | Stock-Energy | 0.09% | -0.07% | EXIT | |
| 50 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.08% | — | — |
According to official SEC Form 13F filings, Privium Fund Management B.V. reported a total U.S. public equity portfolio value of $544.2M across 56 disclosed positions in Q1 2025.
During Q1 2025, Privium Fund Management B.V.'s top holdings by market value included SPOT (21.0%)、TSLA (15.0%)、SHOP (10.4%). The largest single position, SPOT, represented 21.0% of total portfolio value.
In Q1 2025, Privium Fund Management B.V. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.